The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Prescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

The FTC also called for legislative reforms and "is encouraged to see bipartisan interest in Congress and among the states in addressing PBM practices," according to the report. Anjalee Khemlani is ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...